Previous Article | Next Article 
Journal of Virology, January 2001, p. 384-395, Vol. 75, No. 1
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.1.384-395.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
An Epstein-Barr Virus Protein Interacts with
Notch
Shuichi
Kusano1 and
Nancy
Raab-Traub1,2,*
Lineberger Comprehensive Cancer
Center1 and Department of Microbiology & Immunology,2 University of North Carolina,
Chapel Hill, North Carolina 27599
Received 12 June 2000/Accepted 27 September 2000
 |
ABSTRACT |
The Epstein-Barr virus (EBV) BamHI A mRNAs were
originally identified in cDNA libraries from nasopharyngeal carcinoma,
where they are expressed at high levels. The RNAs are differentially spliced to form several open reading frames and also contain the BARF0
open reading frame at the 3' end. One cDNA, RK-BARF0, included a potential endoplasmic reticulum-targeting signal peptide sequence. The RK-BARF0 protein is shown here to interact with the Notch4 ligand
binding domain, using yeast two-hybrid screening,
coimmunoprecipitation, and confocal microscopy. This interaction
induces translocation of a portion of the full-length unprocessed
Notch4 to the nucleus by using the Notch nuclear localization signal.
These effects of RK-BARF0 on Notch intracellular location indicate that
EBV possibly modulates Notch signaling. Unprocessed Notch4 was also detected in immunoprecipitated complexes from EBV-infected cells by
using a rabbit antiserum raised against a BARF0-specific peptide. This
finding provides additional evidence for expression of RK-BARF0 and its
interaction with Notch during EBV infection. In EBV-infected, EBNA2-negative cells, RK-BARF0 induced the expression of EBV latent membrane protein 1 (LMP1), and this induction was dependent on the
RK-BARF0/Notch interaction domain. The activation of LMP1 expression by
RK-BARF0 may be responsible for expression of LMP1 in EBV latent
infections in the absence of EBNA2.
 |
INTRODUCTION |
Epstein-Barr virus (EBV) is linked
to the development of several malignancies including endemic Burkitt's
lymphoma, posttransplantation lymphoma, Hodgkin's disease, and
nasopharyngeal carcinoma (NPC) (35). Infection of B
lymphocytes with EBV in vitro results in immortalized lymphoblastoid
cells (23). Although virus is not produced in transformed
lymphocytes, at least nine viral proteins, including six nuclear
antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, and EBNALP) and three membrane proteins (LMP1, LMP2A, and LMP2B), are expressed (23). Molecular genetic analyses
have demonstrated that EBNA2, EBNA3A, EBNA3C,
EBNALP, and LMP1 are critical for in vitro B-lymphocyte
transformation (5, 22, 27, 46), while EBNA3B,
LMP2A, and LMP2B are dispensable (26, 45). EBNA2 is
the major regulator of viral transcription and transactivates the
expression of LMP1 (50), in part through its interaction
with the DNA binding protein, RBP-J
(CBF1) (14, 15,
19). RBP-J
is a component of the Notch signaling pathway and
is activated through its interaction with the intracellular cytoplasmic
domain of Notch (9, 44). These interactions convert RBP-J
from a repressor of transcription to an activator
(18). EBNA2 seems to be a functional homologue of
activated Notch in EBV-infected cells.
EBV gene expression varies in infected tissue in the distinct diseases
and in different cell types. In NPC, most of the nuclear antigens are
not detected and only EBNA1, LMP1, and LMP2A are consistently
expressed (4, 7, 51). In addition, a family of rightward
transcripts from the BamHI A region was originally identified in NPC, where they are abundantly and consistently expressed
(3, 12, 13, 16). Structural analysis of clones obtained
from a cDNA library of nude-mouse-passaged NPC tumor, C15, revealed
that the BamHI A transcripts are differentially spliced,
giving rise to a family of transcripts, which are 3'-end coterminal
(37, 41). All of the transcripts include the open reading
frame (ORF) BamHI A rightward frame 0 (BARF0) at their 3'
ends, which is predicted to encode a 174-amino-acid (aa) protein. Patients with NPC have antibodies to the in vitro translation product
of this ORF, suggesting that the protein is expressed in vivo
(13). Several additional ORFs are formed by the distinct splices. One cDNA, RK-BARF0, was obtained that extended the BARF0 ORF at the 5' end and would potentially encode a 279-aa protein (37).
The N terminus of RK-BARF0 protein contains a highly hydrophobic region
that resembles an endoplasmic reticulum (ER)-targeting signal peptide
sequence; however, other potential motifs were not identified. To
clarify the function of the RK-BARF0 protein, the yeast
two-hybrid system was used to identify cellular proteins that
potentially interact with RK-BARF0 in epithelial cells. Using an
epithelial cell-specific cDNA library, the RK-BARF0 protein was found to interact with extracellular domain of the Notch family proteins Notch3 and Notch4.
Notch defines a family of transmembrane receptor proteins found in a
variety of organisms including mammals (43). Notch is
synthesized in the ER and further processed in the
trans-Golgi network (TGN) to produce two fragments, which
are then linked through disulfide bonds and transported to the plasma
membrane (2, 34). The amino-terminal fragment is the
extracellular subunit and contains multiple epidermal growth factor
(EGF)-like repeats. Through direct contact with a cell that expresses a
Notch ligand, such as Delta or Jagged, the cytoplasmic domain of Notch is proteolytically cleaved and released from the plasma membrane (38, 42). The cleaved form of Notch is then thought to
interact with modulators and effectors of Notch signaling such as
Deltex and the RBP-J
transcription factor, the mammalian homologue
of the Drosophila Suppressor of Hairless protein
(18). The relative abundance, subcellular location, and
intermolecular interactions of Notch all contribute to the multiplicity
of effects of Notch signaling. This study evaluates the effects of the
RK-BARF0/Notch interaction on Notch and on viral gene expression.
 |
MATERIALS AND METHODS |
Plasmid construction.
The GAL4 DNA binding domain (GAL4BD)
fusions with RK-BARF0 and deletion mutants were constructed in vector
pAS2-1 (Clontech) by PCR amplification of the RK-BARF0 cDNA
fragments encoding aa 12 to 279, 119 to 279, 12 to 128, 12 to 158, 12 to 179, 12 to 209 and 12 to 249 of RK-BARF0, followed by cloning
into the NdeI-SalI or
NdeI-SmaI sites of pAS2-1 to produce
pASRK12-279, pASRK119-279, pASRK12-128, pASRK12-158,
pASRK12-179, pASRK12-209, pASRK12-249, respectively. To express
RK-BARF0 and its C-terminally truncated mutants with epitope tags,
pRK-BARF0, pRK1-179, and pRK1-158 were amplified by PCR from the
RK-BARF0 cDNA fragment, encoding aa 1 to 279, 1 to 179, or 1 to 158 of
RK-BARF0 with FLAG and six-histidine (FLAG/His6) epitope tags in the
carboxy terminus, respectively, and subcloned into the
blunt-ended HindIII site of pMEP4 (Invitrogen). pBARF0
was constructed by PCR amplification of pRK-BARF0, encoding aa 106 to
279 of RK-BARF0 with a C-terminal FLAG epitope tag, and was also
subcloned into pMEP4.
pNot4 containing full-length human Notch4 cDNA was constructed by
fusing four clones from the human lung MATCHMAKER cDNA library (Clontech) and a DNA fragment, containing nucleotides 3011 to 6033 of
Notch4 cDNA (kindly provided by K. Sugaya, National Institute of
Radiological Sciences, Chiba, Japan). To express Notch4 protein with
three myc epitope tags at the C terminus (Notch4-myc), pNot4M3 was
constructed by PCR amplification of pNot4 and subcloning into pA3M
(1), encoding three iterated copies of the myc epitope. To
express intracellular functional domains of truncated Notch4 protein
(TMNotch4) which is lacking the region of Notch4 from aa 1559 to 2010, two DNA fragments, including nt 1 to 3776 and 3770 to 4675, were
isolated by EcoRI-ScaI digestion of pNot4 and PCR
amplification of pNot4, respectively. These DNA fragments were
subcloned into EcoRI-XbaI sites of pA3M to yield
pNot4TM. An inducible Notch4 expression plasmid was synthesized by
transferring an EcoRI-XbaI fragment from the
myc-tagged Notch4 gene from pNot4M3 into the HindIII
site of pMEP4 to yield pNot4(M). All of the DNA constructs were
sequenced at the University of North Carolina
Chapel Hill (UNC)
Automated DNA Sequencing Facility on a model 377 DNA Sequencer
(Perkin-Elmer, Applied Biosystems Division).
Yeast two-hybrid screening and analysis.
Yeast
transformation was performed by the method of Gietz et al.
(11). The yeast strain Y190 (Clontech) was transformed with pASRK12-279, and transformants were plated on Trp
selection medium. GAL4BD-RK12-297 fusion protein expression was verified in single colonies by immunoblotting using the GAL4 DNA-BD antibody (Clontech). The pASRK12-279 transformant was subsequently transformed with the human lung MATCHMAKER cDNA library, and
selection was done on Trp
Leu
His
selection medium in the presence of 25 mM
3-aminotriazole (Sigma). Colonies with moderate to intense growth were
tested for
-galactosidase (
-gal) expression.
To verify the interaction of these clones with RK12-279, positive
colonies were plated on Leu

selection medium containing
10 µg of cycloheximide per ml to
lose pASRK12-279, and Y190 cells
carrying only library-derived
plasmid were mated with the Y187
transformant with pAS2-1, pASRK12-128,
or pASRK119-279.
Library-derived plasmids were recovered by transformation
of competent
DH5

cells with total DNA preparations from Y190
cells followed by
selection for ampicillin resistance. To identify
the interaction domain
of RK-BARF0 with the cDNA clone from yeast
two-hybrid screening,
Y190 was transformed with pASRK12-128, pASRK12-
158, pASRK12-179,
pASRK12-209, pASRK12-249, and pASRK12-279 and
mated with
library-derived plasmid-transformed Y187. Mated yeast
cells were plated
on Trp

Leu

His

selection
medium containing 25 mM 3-aminotriatole and tested
for

-gal
expression.
Cell culture and transfection.
The H1299 cell line, derived
from a human non-small-cell lung carcinoma, was maintained in
Dulbecco's modified Eagle's medium containing penicillin and
streptomycin and supplemented with 10% fetal bovine serum (Gibco BRL).
To obtain H1299 cells expressing FLAG/His6 epitope-tagged RK-BARF0,
RK1-179, RK1-158, BARF0, or pMEP4 and myc epitope-tagged Notch4 or
pA3M, the DNA constructs were transfected using Lipofectin (Gibco BRL).
To obtain stably expressing cell lines, transfected H1299 cells were
selected in the presence of 200 µg of hygromycin B (Boehringer) per
ml and 600 µg of G418 (Gibco BRL) per ml. BJAB and P3HR1 cell lines, derived from EBV-negative and -positive Burkitt's lymphoma,
respectively, were maintained in RPMI 1640 medium containing penicillin
and streptomycin and supplemented with 10% fetal bovine serum. Stable DG75 and Raji cell lines containing the inducible myc epitope-tagged Notch4 or pMEP4 and stable P3HR-1 cell lines containing the inducible FLAG/His6 epitope-tagged RK-BARF0, RK1-179, RK1-158, or pMEP4 were
produced after electroporation and selection in the presence of 200 µg of hygromycin B.
Coimmunoprecipitation of RK-BARF0 and Notch4 from H1299
epithelial cells.
H1299 cells (5 × 105) were
transiently transfected with 2.5 µg of FLAG/His6 epitope-tagged
RK-BARF0, RK1-179, RK1-158, or pMEP4 and 2.5 µg of myc
epitope-tagged Notch4 or pA3M plasmids and induced by addition of 5 µM of CdCl2 approximately 24 h after transfection. The cells were scraped from tissue culture dishes at 16 h
postinduction and lysed for 30 min on ice in lysis buffer (20 mM
Tris-HCl [pH 7.8], 150 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5%
3-[(3-cholamidopropyl)-dimethylammonia]-1-propanesulfonate [CHAPS])
containing 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.5 mM sodium
orthovanadate, and 5 µg of aprotinin per ml. Cell lysates were
clarified by centrifugation. The myc epitope-tagged Notch4 or FLAG/His6
epitope-tagged RK-BARF0 were immunoprecipitated with anti-FLAG M2
monoclonal antibody-conjugated beads (Sigma) or anti-myc monoclonal
antibody-conjugated beads (Santa Cruz) for 8 h at 4°C. The beads
were then washed, and protein complexes were recovered by boiling in
sodium dodecyl sulfate (SDS) sample buffer. Protein samples were
subjected to SDS-polyacrylamide gel electrophoresis (PAGE), and
transferred to Immobilon-P (Millipore). Anti-OctA-probe polyclonal
antibody (Santa Cruz) was used at 0.5 µg per ml for the detection of
FLAG/His6 epitope-tagged RK-BARF0, RK1-179 or RK1-158. Anti-myc probe
polyclonal antibody (Santa Cruz) was used at 0.5 µg per ml for the
detection of myc epitope-tagged Notch4. Horseradish
peroxidase-conjugated goat anti-rabbit antibody (Amersham) was used at
a 1:2,000 dilution as the secondary antibody to detect bound primary
antibody. Reactive proteins were detected by incubation of washed
filters in SuperSignal substrate (Pierce) followed by exposure to X-ray
film (Kodak).
Coimmunoprecipitation of Notch4 from Burkitt's lymphoma cell
lines using rabbit antiserum raised against an RK-BARF0 peptide.
DG75 and Raji cell lines containing the inducible myc epitope-tagged
Notch4 or pMEP4 were induced by addition of 5 µM CdCl2 approximately 36 h after plating. The cell lysates were prepared as described above and were immunoprecipitated using an
affinity-purified rabbit antiserum raised against a BARF0-specific
peptide and Gammabind Sepharose beads (Pharmacia). The beads were
washed, and protein complexes were recovered by boiling in SDS sample
buffer. To detect the myc-tagged Notch4, the protein samples were
subjected to SDS-PAGE, transferred to Immobilon-P, and reacted with
anti-myc epitope monoclonal antibody 9E10 (Santa Cruz) at 0.5 µg per ml.
Immunofluorescence analyses.
H1299 cells containing
inducible FLAG/His6 epitope-tagged RK-BARF0, RK1-179, or RK1-158
and/or myc epitope-tagged Notch4 were induced and analyzed 24 h
postinduction. The cells were fixed with 50% methanol-50% acetone at
20°C and incubated with 10 µg of anti-FLAG M2 monoclonal antibody
per ml and 0.7 µg of anti-myc polyclonal rabbit antibody per ml.
The cells were washed and incubated with fluorescein
isothiocyanate-conjugated goat anti-mouse antibody (Jackson
ImmunoResearch Laboratories) (1:200 dilution) and Lissamine rhodamine-conjugated (LSRC) goat anti-rabbit antibody (Jackson) (1:300 dilution). The cells were washed, mounted with VECTASHIELD mounting medium (Vector), and visualized with a Zeiss Axioplan fluorescence microscope. Confocal microscopy was performed with a Zeiss
confocal microscopy system in the UNC Research Microscopy Laboratory.
Confocal fluorescence images were collected and translated to TIFF
format using NIH Image, and composite figures were created using Adobe
Photoshop 5.0.2.
Preparation of nuclear lysate.
Stable H1299 clones (2 × 106) containing FLAG/His6 epitope-tagged RK-BARF0 or
pMEP4 were plated, transiently transfected with 10 µg of myc-tagged
Notch4-expressing plasmids using Lipofectin, and induced with 5 µM
CdCl2 approximately 24 h after transfection. To purify
the nucleus, the cells were lysed at 24 h postinduction in
hypotonic lysis buffer (10 mM Tris-HCl [pH 7.8], 10 mM NaCl, 3 mM
MgCl2, 0.5% NP-40) containing 5 µg of aprotinin per ml.
Nuclei were isolated by centrifugation at 1,500 × g
for 5 min at 4°C and lysed for 30 min on ice in solubilization buffer
(10 mM Tris-HCl [pH 7.8], 150 mM NaCl, 1 mM EDTA, 0.5% SDS, 0.1%
sodium deoxycholate, 1% NP-40) containing 1 mM PMSF and 5 µg of
aprotinin per ml. To make whole-cell lysates, the cells were lysed in
solubilization buffer. The protein concentrations of nuclear and
whole-cell lysates were quantitated using the DC protein assay reagent
(Bio-Rad). Equivalent amounts of protein were analyzed by
immunoblotting for Notch4-myc, using 1 µg of monoclonal antibody 9E10
per ml, and detected with horseradish peroxidase-conjugated goat
anti-mouse antibody (Amersham). Reactive proteins were detected by
incubation of washed filers in SuperSignal substrate followed by
exposure to X-ray film.
Analysis of LMP1 induction and RK-BARF0 secretion in P3HR1.
Stable P3HR1 cell lines (107) containing FLAG/His6
epitope-tagged RK-BARF0, RK1-179, RK1-158, or pMEP4 were plated and
induced by addition of 1.5 µM CdCl2. The cells were
collected by centrifugation from tissue culture flasks at 48 h
postinduction and lysed for 30 min on ice in RIPA buffer (20 mM
Tris-HCl [pH 7.8], 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.2% SDS,
0.2% sodium deoxycholate) containing 1 mM PMSF, 0.5 mM sodium
orthovanadate, and 5 µg of aprotinin per ml. Cell lysates were
subjected to SDS-PAGE and transferred to Immobilon-P. RK-BARF0,
RK1-179, and RK1-158 were detected with an anti-His probe at 0.5 µg
per ml. LMP1 expression was detected by CS1-4 (DAKO) at a 1:200
dilution. The culture medium was recentrifuged at 3,000 × g for 30 min to remove debris. Supernatants were recovered and
incubated with anti-FLAG M2 beads for 8 h at 4°C. The beads were
then washed with lysis buffer, and protein complexes were recovered by
boiling in SDS sample buffer. Protein samples were subjected to
SDS-PAGE and transferred to Immobilon-P. Anti-His-probe polyclonal
antibody (Santa Cruz Biotechnology) was used at 0.5 µg per ml for the
detection of FLAG/His6 epitope-tagged RK-BARF0, RK1-179, and RK1-158.
 |
RESULTS |
A yeast two-hybrid screen reveals that the extracellular regions of
Notch3 and Notch4 interact with a predicted hydrophobic helix domain of
RK-BARF0.
The RK-BARF0 protein contains a signal peptide-like
sequence at its N terminus; however, other regions of similarity to
known proteins were not identified (37). To further
analyze the function of RK-BARF0, the yeast two-hybrid system was used
to identify cellular proteins that interact with RK-BARF0. The highly
hydrophobic region at the N terminus was deleted, and the DNA encoding
aa 12 to 279 was fused in frame to the GAL4 DNA binding domain
(GAL4BD). The GAL4-activating domain (GAL4AD) was fused to a human lung cDNA library. Approximately 8.5 × 105
transformants were tested for growth on selection medium. Sequence analysis of two positive clones, c36-1 and c41-2, revealed that the cDNAs represented the extracellular domains of human Notch3 and
Notch4, respectively (Fig. 1A). The
extracellular region of Notch proteins has multiple EGF-like repeats,
and Notch3 and Notch4 contain 34 and 29 repeats, respectively
(48). Other protein-interacting domains of Notch,
including the RAM domain and the Notch or ankyrin repeats, were not
contained in the c36-1 and c41-2 clones, suggesting that RK-BARF0 must
interact with Notch through the EGF-like repeat elements.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Schematic representation of the Notch
clones obtained from two-hybrid screening. Clones containing the
EGF-like repeat regions of Notch3 (c36-1) and Notch4 (c41-2) interacted
with RK-BARF0 by yeast two-hybrid screening. A schematic representation
of the Notch4 mutant lacking the entire functional intracellular region
(TMNotch4) that is used this study is shown. The sites of the
proteolytic cleavage for processing and ligand-dependent cleavage are
indicated. Structural motifs within the Notch proteins are indicated as
follows: SS, signal sequence; EGF-LR, EGF-like repeats; LNR,
Notch/lin-12 like repeats; TM, transmembrane domain; R, RAM domain; N,
NLS; AR, cdc10/ankyrin repeats; P, PEST sequence. (B) Schematic
representation of C-terminal deletion mutants of RK-BARF0 and -gal
activity in the yeast mating assay. The full-length (aa 12 to 279) and
five C-terminal deletion (aa 12 to 249, 12 to 209, 12 to 179, 12 to
158, and 12 to 128) constructs of RK-BARF0 fused to GAL4BD were
transfected in yeast Y190 cells and mated with yeast Y187 cells
containing the Notch4 EGF-like repeats region/GAL4AD fusion construct.
Mated yeast cells were plated on Trp Leu
medium plates, and the relative -gal activity was determined. The
time taken for more than 80% of the colonies to become blue is shown:
+++, <1 h; ++, 1 to 3 h; +, 3 to 6 h; , no blue colonies
is >8 h. (C) Growth patterns of mated yeast strains on
His selective medium. Mated yeast cells were plated on
Trp Leu medium plates and Trp
Leu His medium plates and incubated at
30°C for 5 days. (D) The predicted secondary structure of RK-BARF0
was determined using a 3D-1D compatibility algorithm. Bold letters
indicate the sequence of the interaction-domain of RK-BARF0 with Notch.
(E) The predicted hydrophobicity of the RK-BARF0 protein was determined
by Kyte-Doolittle analysis. Bold square indicates the hydrophobicity of
the interaction domain of RK-BARF0 with Notch.
|
|
To verify these interactions between RK-BARF0 and the two Notch clones,
yeast Y190 cells containing the c41-2/GAL4AD fusion
were mated with
Y187 transformants carrying pAS2-1, encoding GAL4BD
only, pASRK12-128,
encoding the amino-terminal 12 to 128 aa of
RK-BARF0 fused to GAL4BD,
or pASRK119-279, encoding the carboxy
terminal 119 to 279 aa of
RK-BARF0 fused to GAL4BD. After mating,
the yeast cells were plated on
selective medium. Only yeast containing
pASRK119-279, representing the
carboxy terminus of RK-BARF0, could
grow in the absence of histidine
and also had high levels of

-gal
activity (data not shown). These
results revealed that aa 119
to 279 of RK-BARF0 interact with
Notch4. To further define the
Notch interaction domain of RK-BARF0,
five C-terminal deletion
constructs of RK-BARF0 fused to GAL4BD were
tested for Notch4
interaction by mating and yeast two-hybrid analysis
(Fig.
1B).
The yeast strains carrying RK12-279, RK12-249, RK12-209,
and RK12-179
could grow on the selective medium with moderate to high
levels
of

-gal activity, while the deletion constructs representing
the amino terminus, RK12-128 and RK12-158 could not grow on selective
media (Fig.
1B and
1C). Similar results were obtained from mating
analyses with these mutants using yeast strains carrying human
Notch3
clone c36-1 (data not shown). This analysis indicated that
the region
of RK-BARF0 between aa 159 and 179 is necessary for
interaction with
Notch. The hydrophobicity plot by Kyte-Doolittle
analysis
(
25) and potential secondary structure predicted by
3D-1D
compatibility algorithm (
21) indicated that the region
between aa 159 and 179 of RK-BARF0 has a hydrophobic helical structure,
suggesting that RK-BARF0 interacts with the extracellular region
of
Notch protein through a hydrophobic helix (Fig.
1D and
E).
RK-BARF0 associates with Notch4 in vivo.
To examine the
interaction of RK-BARF0 and Notch4 in vivo, a full-length Notch4
cDNA was synthesized and cloned in frame into a pA3M, which is a
pcDNA3 plasmid containing three repeated c-myc epitopes at the
carboxy terminus under the control of the human cytomegalovirus
immediate-early promoter. Three RK-BARF0 constructs, RK-BARF0 (aa 1 to
279), RK1-179, and RK1-158, containing FLAG/His6 epitopes at the C
terminus, were also prepared and cloned into pMEP4, which contains the
inducible human metallothionein promoter. We have consistently achieved
excellent protein expression in epithelial cells by using the
metallothionein promoter, which enables expression of potentially toxic
proteins in cell lines. The Notch4 and RK-BARF0 plasmids were
transfected into the human epithelial cell line, H1299. After induction
with CdCl2, lysates were prepared and complexes containing
RK-BARF0 were immunoprecipitated using the anti-FLAG M2 monoclonal
antibody. Western blot analyses of the immunoprecipitated complexes
indicated that RK-BARF0 and the C-terminal deletion mutant, RK1-158,
were expressed at similar levels, with somewhat lower expression of
RK1-179 (Fig. 2A). Although equivalent
amounts of transfected Notch4 were detected in the total-cell lysates,
immunoblotting with an anti-myc polyclonal antibody to identify myc
epitope-tagged Notch4 (Notch4-myc) detected Notch4 in precipitated
complexes containing RK-BARF0 and RK1-179 but not RK1-158 (Fig. 2B
and C). This observation is consistent with the results of yeast
two-hybrid analysis and indicated that aa 159 to 179 of RK-BARF0 are
also necessary for the interaction between RK-BARF0 and Notch in vivo.
Interestingly, the unprocessed full-length form of Notch4 and also the
intracellular C-terminal, processed form of Notch4, which lacks the
EGF-like repeats, were detected in complexes with both RK-BARF0 and
RK1-179. The presence of the intracellular fragment of processed Notch
in the precipitated RK-BARF0 complexes indicates that RK-BARF0 also
interacts with processed Notch4 containing both the extracellular and
intracellular subfragments, joined by cysteine bonds. These bonds are
denatured during SDS-PAGE such that only the intracellular Notch
fragment which contains the myc epitope is detected by Western
blotting. Comparison of the amount of Notch4 present in the total-cell
lysate with that detected in the RK-BARF0 containing complexes
indicated that approximately 15% of the transfected Notch4 was present
in the complexes. However, RK-BARF0 also interacts with Notch1 (data not shown). This interaction with endogenously expressed Notch1 would
decrease the amount available for interaction with transfected Notch4.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 2.
RK-BARF0 associates with processed and unprocessed forms
of Notch4 in vivo. H1299 cells (5 × 105) were
transiently transfected with both FLAG/His6-tagged RK-BARF0 (aa 1 to
279), RK1-179, RK1-158, or pMEP4 and Notch4myc or pA3M. RK-BARF0,
RK1-179, and RK1-158 were induced with 5 µM CdCl2 for
16 h, immunoprecipitated, and analyzed on immunoblots. (A)
Immunoblot with an anti-FLAG antibody to identify RK-BARF0, RK1-179,
and RK1-158 in the immunoprecipitated RK-BARF0 complexes. (B)
Immunoblot analysis with anti-myc antibody to identify Notch4
expression in the transfected cells. (C) Identification of processed
and unprocessed forms of Notch4 in the immunoprecipitated (IP) RK-BARF0
complexes using anti-myc epitope polyclonal antibodies. (D) Immunoblot
with anti-myc antibody to identify Notch4 in the immunoprecipitated
Notch4 complexes. (E) Immunoblot analysis with antihistidine antiserum
to determine the expression of RK-BARF0, RK1-179, and RK1-158 in the
transfected cells. (F) Detection of RK-BARF0 and RK1-179, using
antihistidine antibody in the Notch4 complexes immunoprecipitated with
anti-myc antibody.
|
|
The interaction of Notch4 with RK-BARF0 was confirmed in the reciprocal
immunoprecipitation. Immunoblot analysis of the immunoprecipitated
Notch4-containing complexes detected equivalent amounts of Notch4
in
the complexes (Fig.
2D). Using an anti-His polyclonal antibody,
immunoblots of the total-cell lysates indicated that RK-BARF0
and
RK1-179 were expressed at equal levels and that there was
a somewhat
greater expression of RK1-158 (Fig.
2E). In agreement
with the data
presented above, only RK-BARF0 and RK1-179 were
detected in the
Notch4-containing immunoprecipitated complexes
(Fig.
2F).
It is known that Notch has a signal sequence in the N terminus, is
synthesized in the ER, and is processed in the TGN (
2).
Since the RK-BARF0 protein also has a signal peptide-like sequence
at
its amino terminus, it is likely to also be synthesized in
the ER. The
interaction of RK-BARF0 with unprocessed Notch suggests
that the
RK-BARF0/Notch interaction occurs in the ER prior to
Notch processing.
The BARF0 ORF, which is present at the 3' end
of all of the variably
spliced
BamHI A transcripts, lacks the
N-terminal
hydrophobic sequence of RK-BARF0 and contains aa 106
to 279 of
RK-BARF0, including the Notch-interacting domain. BARF0,
tagged with
the FLAG epitope, was cloned into the pMEP4 vector,
and RK-BARF0 and
BARF0 were transfected with Notch4-myc into H1299
cells. After
induction of expression and precipitation, immunoblot
analysis
indicated that both RK-BARF0 and BARF0 were present in
the precipitated
complexes (Fig.
3A). Notch4 was expressed
at
equivalent levels in each of the transfections (Fig.
3B). The
processed form of Notch4 was present in the immunoprecipitated
complexes with BARF0, but only trace levels of unprocessed Notch
were
present, comparable to that detected in precipitates prepared
from
cells containing the pMEP4 vector control (Fig.
3C). This
observation
indicates that the potential protein product of the
BARF0 ORF also can
interact with Notch and suggests that the N-terminal
hydrophobic region
of RK-BARF0 is necessary for the interaction
with unprocessed Notch4.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 3.
BARF0 interacts with processed Notch. (A) Immunoblot of
RK-BARF0 or BARF0 (aa 106 to 279) after induction and
immunoprecipitation (IP) with an anti-FLAG polyclonal antibody. (B)
Immunoblot analysis of whole cell lysates to identify Notch4 expression
after transfection. (C) Identification of processed and unprocessed
forms of Notch4 in the RK-BARF0 and BARF0 immunoprecipitated complexes.
WB, Western blot.
|
|
RK-BARF0 induces the translocation of unprocessed Notch4 to the
nucleus.
To further analyze the interaction between RK-BARF0 and
Notch4, the intracellular location of RK-BARF0 and Notch was
determined. Stable cell lines containing Notch4 and the
FLAG/His6-tagged RK-BARF0 and deletion mutants in H1299 cells were
prepared and analyzed for protein expression and intracellular location
by using the anti-FLAG M2 monoclonal antibody and a
fluorescein-conjugated anti-mouse secondary antibody to detect
RK-BARF0. RK-BARF0 and RK1-179 were predominantly found in a punctate
staining pattern throughout the nucleus and in the perinuclear region,
possibly representing the ER (Fig.
4A). RK-BARF0 was also
mainly detected in the nuclear pellet of biochemically fractionated
RK-BARF0-expressing H1299 cells (data not shown). However RK1-158,
which does not interact with Notch4 protein, was localized throughout
the cytoplasm (Fig. 4A). These data indicate that the region of
RK-BARF0 which is required for the interaction with Notch protein is
also necessary for the nuclear localization of RK-BARF0.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 4.
RK-BARF0 Colocalizes with Notch4 in the nucleus. (A)
Cell lines containing both Notch4-myc and FLAG/His6-tagged RK-BARF0,
RK1-179, RK1-158 or pMEP4 expression plasmids were induced and
stained using a monoclonal antibody to FLAG and FITC-conjugated
anti-mouse immunoglobulin G (IgG) to identify RK-BARF0. (B) Cell lines
containing Notch4-myc or both Notch4-myc and FLAG/His6-tagged RK-BARF0, RK1-158, or the pMEP4 vector were stained with
anti-myc polyclonal antibody and LSRC-conjugated anti-rabbit IgG to
identify Notch4. (C) A stable cell line containing Notch4-myc and
FLAG/His6-tagged RK-BARF0 was stained with anti-FLAG M2 monoclonal
antibody and anti-myc polyclonal antibody using FITC-conjugated
anti-mouse IgG to detect RK-BARF0 and RISC-conjugated anti-rabbit IgG
to detect Notch4. Confocal images were collected, and composite figures
were created using Adobe Photoshop 5.0.2. The differential interference
contrast microscopy image of the cell is presented. (D) A cell line
containing the extracellular to transmembrane region of Notch4
(TMNotch4)-myc in pA3M and FLAG/His6-tagged RK-BARF0 was stained with a
monoclonal FLAG and FITC-conjugated anti-mouse IgG to identify RK-BARF0
and anti-myc polyclonal antibody and LSRC-conjugated anti-rabbit IgG to
identify TMNotch4.
|
|
To determine if the interaction with RK-BARF0 affected Notch
localization, stable H1299 cell lines expressing the Notch4 protein
alone or in the presence of RK-BARF0 were analyzed. In the absence
of
RK-BARF0, the Notch4-myc protein was found throughout the cytoplasm,
with no staining of the nucleus (Fig.
4B, Notch4 with Vector).
In
contrast, in the presence of RK-BARF0, Notch4 was detected
in the
nucleus and perinuclear region (Fig.
4B, Notch4 with RK-BARF0).
When
Notch4 was coexpressed with the RK1-158 deletion mutant of
RK-BARF0
which cannot interact with Notch, Notch4 remained in
the cytoplasm
(Fig.
4B, Notch4 with RK1-158). These data suggest
that the
interaction of RK-BARF0 with Notch4 protein induces the
nuclear
localization of Notch4. The staining for RK-BARF0 and
Notch4 in
the same cell in Fig.
4A, RK-BARF0 with Notch4, and
Fig.
4B, Notch4
with RK-BARF0, suggested colocalization. The interaction
and
colocalization of RK-BARF0 and Notch4 in the nucleus were
confirmed
using confocal microscopy. RK-BARF0 and Notch4 protein
were detected in
punctate nuclear granules using fluorescein-conjugated
secondary
antiserum for detection of RK-BARF0 and rhodamine-conjugated
secondary
antiserum for detection of Notch4. The colocalized proteins
are
indicated in yellow (Fig.
4C). The cell and nuclear shape
were revealed
by differential interference contrast microscopy
(Fig.
4C).
RK-BARF0 does not have a potential nuclear localization signal (NLS),
and the deletion mutant of RK-BARF0 that lacks the Notch-interacting
region does not translocate to the nucleus. However, an NLS is
present
in the intracellular portion of Notch4, and forms of Notch
that lack
the extracellular domain localize to the nucleus (
1,
42).
To determine if the localization of RK-BARF0 and Notch
in the nucleus
is dependent on the Notch NLS, a deleted form of
Notch
containing the extracellular domain and transmembrane region
and lacking the entire intracellular region containing the NLS
(TMNotch4) was coexpressed with RK-BARF0 (Fig.
4D). RK-BARF0
(Fig.
4D, RK-BARF0 with TMNotch4) and TMNotch4 (Fig.
4D, TMNotch4
with
RK-BARF0) were both detected in the cytoplasm. These data indicate
that the translocation of the RK-BARF0/Notch complex to the nucleus
is
dependent on the Notch NLS. The interaction of RK-BARF0 with
the Notch
extracellular domain apparently affects the tertiary
structure of Notch
such that the Notch/RK-BARF0 complex is transported
to the nucleus
through the Notch
NLS.
The translocation of Notch4 protein to the nucleus was also examined by
transfection of Notch4 into the H1299 cell line containing
RK-BARF0 in
the pMEP4 inducible-expression plasmid. Analysis of
the whole-cell
lysates detected equivalent expression of unprocessed
Notch4 in
whole-cell lysates from the transfected cell lines with
or without
induction of the pMEP4 promoter (Fig.
5A). The presence
of transfected Notch4
in the nuclear fraction was determined before
and after induction of
RK-BARF0 expression. Unprocessed Notch4
was not detected in equivalent
amounts of nuclear lysate from
cells that contained the pMEP4 vector or
in cells that contained
RK-BARF0 without induction. However, after
induction of RK-BARF0
expression, a portion of unprocessed Notch4 was
detected in the
nuclear fraction (Fig.
5B). The amount of Notch4
detected in 7
µg of nuclear protein after induction of RK-BARF0
expression was
two- to threefold greater than that detected in 23 µg
of nuclear
protein from the vector-containing cells. The detection of
unprocessed
Notch4 in the nuclear fraction only after induction of
RK-BARF0
expression confirmed that the nuclear localization of the
unprocessed
form of Notch protein is dependent on of RK-BARF0.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
RK-BARF0 induces the translocation of unprocessed Notch4
to the nucleus. Stable cell clones containing FLAG/His6 epitope-tagged
RK-BARF0 or pMEP4 expression plasmids were transiently transfected with
Notch4-myc and treated for 24 h with 8 µM CdCl2 or
left untreated. Protein (40 µg) of whole-cell lysates (A) and 7 or 23 µg of nuclear lysates (B) were subjected to SDS-PAGE and analyzed for
the presence of Notch4-myc by using anti-myc (9E10) antibody.
|
|
RK-BARF0 has an ER-targeting signal and can be secreted.
The
interaction of RK-BARF0 with unprocessed Notch suggests that the
amino-terminal hydrophobic region of RK-BARF0 is indeed an ER-targeting
sequence and that RK-BARF0 and Notch are synthesized and interact in
the ER prior to Notch processing in the Golgi. In H1299 cells, 2 h
after induction, RK-BARF0 was detected in the perinuclear region,
characteristic of the ER, and by 4 h after induction, RK-BARF0 was
present in the nucleus in some cells (Fig. 6A).


View larger version (67K):
[in this window]
[in a new window]
|
FIG. 6.
RK-BARF0 is expressed in the ER and can be secreted. (A)
Stable H1299 cell lines containing FLAG/His6-tagged RK-BARF0 were
induced by 5 µM CdCl2 to express RK-BARF0, and cells were
stained 2 and 4 h postinduction with anti-FLAG antibody and
FITC-conjugated anti-mouse antibody to determine RK-BARF0 localization.
(B) Culture medium (8 ml/5 × 106 cells) of induced
P3HR1 cells containing FLAG/His6-tagged RK-BARF0, RK1-179,
RK1-158, or pMEP4 expression plasmids was incubated with anti-FLAG M2
beads. Immunoprecipitates (I.P.) from culture medium and 50 µg of
protein of whole-cell lysates were subjected to SDS-PAGE.
FLAG/His6-tagged RK-BARF0, RK1-179, or RK1-158 were detected with
the anti-His- probe polyclonal antibody. Solid arrows indicate the
protein bands which are identified in both whole-cell lysate and cell
culture media; open arrows indicate the protein bands which are present
only in the cell culture media. D.L., direct load; WB, Western blot.
|
|
A signal peptide sequence not only suggests that RK-BARF0 is targeted
to the ER but also suggests that RK-BARF0 could be processed
and
secreted into the medium. To determine if RK-BARF0 can be
secreted,
cell lines stably expressing RK-BARF0, RK1-179, and
RK1-158 were
established in the P3HR1 cell line, which expresses
a very low level of
endogenous Notch1. The full-length proteins
were detected in the
whole-cell lysates; however, RK1-158, which
does not interact with
Notch, and a smaller form, probably representing
RK1-158, after
cleavage of the signal peptide, were abundant in
the culture medium
(Fig.
6B). RK1-179 and its cleaved form were
also clearly evident;
however, only trace levels of RK-BARF0 and
a smaller form were
detected. These data suggest that RK-BARF0
can be processed and
secreted. The greatly increased secretion
of RK1-158, which does not
interact with Notch and does not translocate
to the nucleus, suggests
that the interaction with Notch may inhibit
the secretion of RK-BARF0.
RK-BARF0 induces LMP1 expression in EBNA2-negative P3HR1
cells.
EBNA2 is the major viral transactivator of expression
of the EBV oncogene LMP1. Transactivation of LMP1 by EBNA2 is
complex; however, it is partially mediated through its interaction with RBP-J
. Interestingly, in EBV-infected NPC, LMP1 is expressed in the
absence of EBNA2. P3HR1 is an EBV-positive Burkitt's lymphoma cell
line in which the EBNA2-encoding region is deleted, and it expresses very low levels of LMP1. To determine if the RK-BARF0/Notch interaction positively affects expression of LMP1 in the absence of
EBNA2, stable cell lines containing RK-BARF0 and the noninteracting deletion, RK1-158, were derived from P3HR1 cells and analyzed for LMP1
expression. After induction of expression of RK-BARF0 in P3HR1 cells,
the amount of LMP1 was considerably increased in comparison with that
in P3HR1 cells expressing RK1-158, the mutant that does not interact
with Notch, or the vector control, pMEP4 (Fig.
7). These results indicate that RK-BARF0
can activate LMP1 expression in an EBNA2-independent manner through
the Notch interaction domain.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 7.
RK-BARF0 induces LMP1 expression in EBNA2-negative
P3HR1 cells. Stable cell lines containing FLAG/His6-tagged RK-BARF0,
RK1-158, or pMEP4 expression plasmids were treated for 48 h with
1.5 µM CdCl2. (A) Immunoblot analysis of 80 µg of
protein of whole-cell lysates with an anti-His-probe to identify
RK-BARF0 and RK1-158. (B) Immunoblot analysis of 60 µg of protein of
whole-cell lysates by anti-LMP1 (CS1-4) to identify LMP1. WB, Western
blot.
|
|
Coimmunoprecipitation of RK-BARF0 and Notch4 from the EBV-infected
Raji cell line.
We have previously produced a rabbit antiserum to
a BARF0-specific peptide representing aa 115 to 132 of RK-BARF0
(10). This antiserum specificially reacts with a
glutathione transferase-BARF0 fusion protein, in vitro-translated
BARF0, and transfected RK-BARF0 (10). The antiserum also
cross-reacts with a cellular protein that is abundant in DG75 and other
EBV-negative Burkitt's lymphoma cells (24). This protein
has since been identified as major histocompatibility complex (MHC)
class II (T. Sculley, personal communication). Since expression of
class II is induced by EBV infection and the estimated molecular weight
of RK-BARF0 is the same as that of MHC class II, the detection of
endogenously expressed RK-BARF0 using this reagent is obscured. To use
the RK-BARF0/Notch interaction to assess the expression of RK-BARF0
expression in EBV-infected cells, stable cell lines containing
myc-tagged Notch4 in pMEP4 were established from the EBV-positive cell
line Raji and the EBV-negative cell line DG75. Expression of Notch 4 was induced by treatment with 5 µM CdCl2 for 36 h
prior to preparation of cell lysates. Immunoblot analysis indicated
that Notch4 expression was induced in both cell lines with increased
expression in DG75 cells (Fig. 8A). The
RK-BARF0 antiserum was enriched by affinity purification with the BARF0
specific peptide and used for immunoprecipitation from the
Notch4-expressing Raji and DG75 cells. Immunoblot analysis using the
anti-myc monoclonal antibody detected Notch4 in the immunoprecipitated
complexes from Raji cells but not from DG75, despite the higher level
of Notch4 expression in these cells (Fig. 8B). In addition, Notch4 was
not detected after immunoprecipitation of MHC class II from induced
Raji or DG75 cells (data not shown). Immunoprecipitation of unprocessed
Notch4 from the EBV-infected Raji cell line, using the
BARF0-specific antibody, provides indirect evidence that the
RK-BARF0 protein is expressed in EBV-positive Raji cells.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 8.
RK-BARF0 peptide rabbit antiserum precipitates
transfected Notch4 protein from Raji cells but not from DG75. Stable
cell lines containing myc-tagged Notch4 or pMEP4 expression plasmids
were treated for 36 h with 5 µM CdCl2. (A) Protein
(100 µg) from cell lysates was subjected to SDS-PAGE, and myc-tagged
Notch4 was identified using the 9E10 monoclonal antibody. (B) Protein
from cell lysates (1,250 µg) was precipitated using peptide
affinity-purified rabbit antiserum against RK-BARF0 (10).
Immunoprecipitates (IP) were subjected to SDS-PAGE, and myc-tagged
Notch4 was identified using 9E10 monoclonal antibody. WB, Western
blot.
|
|
 |
DISCUSSION |
Notch4 (also called Int3) is a member of the Notch receptor family
and is thought to be involved in endothelial and epithelial differentiation in mammals (48, 49). Notch was originally identified as a Drosophila neurogenic gene required for
correct segregation of epidermal cells from neuronal cell precursors
during embryogenesis, but subsequent studies demonstrated that Notch is
widely expressed during embryonic and adult development and mediates
many cell-cell interactions during fly development (8). Notch directly activates gene expression through its interaction with
the DNA binding protein RBP-J
, the mammalian homologue of the
Drosophila Suppressor of Hairless protein. The major
transcriptional regulator of EBV during latent infection in B
lymphocytes, EBNA2, also directly interacts with RBP-J
in a
manner analogous to that of Notch and activates cellular and viral
promoters through RBP-J
(14, 15, 19). The activated
form of mouse Notch1 can substitute for EBNA2 and can transactivate
the EBV LMP1 promoter (17). The interaction of RBP-J
with EBNA2 is apparently carefully regulated and is thought to be
affected by at least three other EBV proteins, EBNA3A, EBNA3B,
and EBNA3C, which also interact with RBP-J
and possibly
negatively regulate EBNA2-mediated transactivation (36, 52).
The data presented here indicate that the potential EBV protein,
RK-BARF0, interacts with the Notch in the ER prior to processing in the
TGN. The biogenesis of Notch is complex, with expression in the ER,
processing in the TGN, and cleavage at the plasma membrane to release
the cytoplasmic fragment, which activates cellular gene expression
through its interaction with RBP-J
(18). The interaction of RK-BARF0 with the Notch ligand binding domain apparently unmasks the Notch NLS and induces translocation of unprocessed Notch to
the nucleus. This interaction also results in a decrease in the levels
of total Notch (data not shown). These effects on Notch may inhibit
Notch activation and signaling and also reduce the amount of RBP-J
that is bound to Notch. This effect might facilitate the interaction of
EBNA2 with RBP-J
to activate the expression of LMP1.
However, in most of the malignancies associated with EBV, including
NPC, LMP1 is expressed in the absence of EBNA2 (35). The BamHI A RNAs are abundantly expressed in NPC and were
originally identified in cDNA libraries from NPC RNA (12,
16). The levels of these RNAs are considerably lower in
transformed lymphocytes, and it is difficult to detect the mRNAs on
Northern blots (12, 37). The difference in the relative
abundance of the RNAs may indicate that the proteins potentially
encoded by these RNAs are predominantly expressed and function in
infections where the EBNA2 and EBNA3 proteins are not expressed.
The data presented here indicate that the RK-BARF0/Notch
interaction can induce the expression of LMP1 in the absence of
EBNA2. The regulation of LMP1 expression is complex, and
EBNA2-dependent and -independent elements have been identified
(47). An ATF/CRE element in the promoter mediates
EBNA2-independent activation of the LMP1 promoter and
binds ATF1, ATF2, and c-Jun (39). The Notch/RK-BARF0 interaction may activate LMP1 expression
through effects on RBP-J
or through other pathways affected
by Notch. Notch interacts with the cytoplasmic protein Deltex,
which inhibits activation of the c-Jun terminal kinase (JNK), and
recent studies also implicate Notch in activation of NF-
B
p50-containing complexes (6, 28-30, 32, 33). Notch can
also affect gene expression independently of its interaction with
RBP-J
. Dominant negative forms of RBP-J
do not block the effects
of Notch on myogenic differentiation of C2C12 cells, and Notch mutants
lacking the RBP-J
binding site and the Notch NLS can still activate
transcription (31). Notch4 is frequently rearranged by
mouse mammary tumor virus integration, and Notch gene family members
are activated through chromosomal translocations. In human tumors,
novel Notch4 mRNAs have also been identified that contain the
intracellular domain and lack the RBP-J
binding site
(20).
Multiple potential ORFs are formed by the differentially spliced
BamHI A mRNAs; however, the proteins encoded by the RNAs remain unidentified. The most abundant 4.8-kb mRNA was originally predicted to have the structure found in the RB2 cDNA, and the two
largest ORFs identified in this cDNA are the RK103 ORF and the RB2
ORF (37). A recent report has confirmed the splice donor and acceptor sites described in the RB2 cDNA. The data indicate that the RB2 ORF is identical to an ORF identified in the A73 cDNA
and that the RPMS1 ORF, originally described in the C22.2 cDNA, is
identical to the RK103 ORF (37, 40). These ORFs encode proteins when expressed with a recombinant epitope tag, and potential interacting proteins have been identified using the yeast two hybrid.
Interestingly, RPMS1 also interacts with RBP-J
and negatively regulates a synthetic promoter containing four copies of the
EBNA2-responsive element of the BamHI C promoter
(40).
Clearly, these ORFs can encode proteins that have interesting biologic
properties; however, antisera that specifically recognize the RPMS1 or
RB2 protein products have not yet been produced. A previously described
rabbit antiserum produced using a BARF0-specific peptide was shown to
identify a glutathione S-transferase-BARF0 fusion protein,
in vitro-translated RK-BARF0, and transfected RK-BARF0
(10). This antiserum was subsequently shown to also react
with a cellular protein that was expressed at high levels in the
EBV-negative Burkitt's lymphoma cell line DG75 and other EBV-negative
B-cell lines (24). This cellular protein was identical in
size to transfected RK-BARF0 and obscured the detection of the
authentic protein in EBV-infected cells or tissues. In this study, the
antiserum was affinity purified using the BARF0 peptide to reduce
reactivity with the cellular protein and the interaction between Notch
and RK-BARF0 was analyzed. The detection of unprocessed Notch4 in the
complexes immunoprecipitated from the EBV-positive Raji cell line but
not from the-EBV negative DG75 cell line provides indirect evidence for
the expression of RK-BARF0.
The direct interaction of RK-BARF0 with Notch provides another
mechanism through which EBV affects or usurps the Notch signaling pathway. The protein product of the RK-BARF0 ORF is the first viral
protein that has been shown to interact with Notch and affect its
intracellular location. The interaction of several EBV proteins with
components of the Notch signaling pathway highlights the multiple
mechanisms that regulate this pathway and affect cellular and viral
gene expression and growth control.
 |
ACKNOWLEDGMENTS |
We thank S. Milgram and K. Sugaya for kindly providing the
amplified human lung cDNA library and partial human Notch4 clone, respectively.
This work was supported by NIH grant CA32979 (N.R.-T.) and by the
Yamanouchi Foundation for Research on Metabolic Disorders and The
Ryoichi Naito Foundation for Medical Research (S.K.).
 |
FOOTNOTES |
*
Corresponding author, Mailing address: Lineberger
Comprehensive Cancer Center, University of North Carolina, CB 7295, Chapel Hill, NC 27599-7295. Phone: (919) 966-1701. Fax: (919) 966-9673. E-mail: nrt{at}med.unc.edu.
 |
REFERENCES |
| 1.
|
Aster, J. C.,
E. S. Robertson,
R. P. Hasserjian,
J. R. Turner,
E. Kieff, and J. Sklar.
1997.
Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription.
J. Biol. Chem.
272:11336-11343[Abstract/Free Full Text].
|
| 2.
|
Blaumueller, C. M.,
H. Qi,
P. Zagouras, and S. Artavanis-Tsakonas.
1997.
Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane.
Cell
90:281-291[CrossRef][Medline].
|
| 3.
|
Brooks, L. A.,
A. L. Lear,
L. S. Young, and A. B. Rickinson.
1993.
Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency.
J. Virol.
67:3182-3190[Abstract/Free Full Text].
|
| 4.
|
Busson, P.,
R. McCoy,
R. Sadler,
K. Gilligan,
T. Tursz, and N. Raab-Traub.
1992.
Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma.
J. Virol.
66:3257-3262[Abstract/Free Full Text].
|
| 5.
|
Cohen, J. I.,
F. Wang,
J. Mannick, and E. Kieff.
1989.
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.
Proc. Natl. Acad. Sci. USA
86:9558-9562[Abstract/Free Full Text].
|
| 6.
|
Diederich, R. J.,
K. Matsuno,
H. Hing, and S. Artavanis-Tsakonas.
1994.
Cytosolic interaction between deltex and Notch ankyrin repeats implicates deltex in the Notch signaling pathway.
Development
120:473-481[Abstract].
|
| 7.
|
Fahraeus, R.,
H. L. Fu,
I. Ernberg,
J. Finke,
M. Rowe,
G. Klein,
K. Falk,
E. Nilsson,
M. Yadav,
P. Busson, et al.
1988.
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma.
Int. J. Cancer
42:329-338[Medline].
|
| 8.
|
Fortini, M. E., and S. Artavanis-Tsakonas.
1993.
Notch: neurogenesis is only part of the picture.
Cell
75:1245-1247[CrossRef][Medline].
|
| 9.
|
Fortini, M. E., and S. Artavanis-Tsakonas.
1994.
The suppressor of hairless protein participates in notch receptor signaling.
Cell
79:273-282[CrossRef][Medline].
|
| 10.
|
Fries, K. L.,
T. B. Sculley,
J. Webster-Cyriaque,
P. Rajadurai,
R. H. Sadler, and N. Raab-Traub.
1997.
Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus.
J. Virol.
71:2765-2771[Abstract].
|
| 11.
|
Gietz, R. D.,
R. H. Schiestl,
A. R. Willems, and R. A. Woods.
1995.
Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure.
Yeast
11:355-360[CrossRef][Medline].
|
| 12.
|
Gilligan, K.,
H. Sato,
P. Rajadurai,
P. Busson,
L. Young,
A. Rickinson,
T. Tursz, and N. Raab-Traub.
1990.
Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma.
J. Virol.
64:4948-4956[Abstract/Free Full Text].
|
| 13.
|
Gilligan, K. J.,
P. Rajadurai,
J. C. Lin,
P. Busson,
M. Abdel-Hamid,
U. Prasad,
T. Tursz, and N. Raab-Traub.
1991.
Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo.
J. Virol.
65:6252-6259[Abstract/Free Full Text].
|
| 14.
|
Grossman, S. R.,
E. Johannsen,
X. Tong,
R. Yalamanchili, and E. Kieff.
1994.
The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein.
Proc. Natl. Acad. Sci. USA
91:7568-7572[Abstract/Free Full Text].
|
| 15.
|
Henkel, T.,
P. D. Ling,
S. D. Hayward, and M. G. Peterson.
1994.
Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa.
Science
265:92-95[Abstract/Free Full Text].
|
| 16.
|
Hitt, M. M.,
M. J. Allday,
T. Hara,
L. Karran,
M. D. Jones,
P. Busson,
T. Tursz,
I. Ernberg, and B. E. Griffin.
1989.
EBV gene expression in an NPC-related tumour.
EMBO J.
8:2639-2651[Medline].
|
| 17.
|
Hofelmayr, H.,
L. J. Strobl,
C. Stein,
G. Laux,
G. Marschall,
G. W. Bornkamm, and U. Zimber-Strobl.
1999.
Activated mouse Notch 1 transactivates Epstein-Barr virus nuclear antigen 2-regulated viral promoters.
J. Virol.
73:2770-2780[Abstract/Free Full Text].
|
| 18.
|
Honjo, T.
1996.
The shortest path from the surface to the nucleus: RBP-J kappa/Su(H) transcription factor.
Genes Cells
1:1-9[Abstract].
|
| 19.
|
Hsieh, J. J., and S. D. Hayward.
1995.
Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2.
Science
268:560-563[Abstract/Free Full Text].
|
| 20.
|
Imatani, A., and R. Callahan.
2000.
Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines.
Oncogene
19:223-231[CrossRef][Medline].
|
| 21.
|
Ito, M.,
Y. Matsuo, and K. Nishikawa.
1997.
Prediction of protein secondary structure using the 3D-1D compatibility algorithm.
Comput. Appl. Biosci.
13:415-424[Abstract/Free Full Text].
|
| 22.
|
Kaye, K. M.,
K. M. Izumi, and E. Kieff.
1993.
Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.
Proc. Natl. Acad. Sci. USA
90:9150-9154[Abstract/Free Full Text].
|
| 23.
|
Kieff, E.
1996.
Epstein-Barr virus and its replication.
Lippincott-Raven, Philadelphia, Pa.
|
| 24.
|
Kienzle, N.,
M. Buck,
S. Greco,
K. Krauer, and T. B. Sculley.
1999.
Epstein-Barr virus-encoded RK-BARF0 protein expression.
J. Virol.
73:8902-8906[Abstract/Free Full Text].
|
| 25.
|
Kyte, J., and R. F. Doolittle.
1982.
A simple method for displaying the hydropathic character of a protein.
J. Mol. Biol.
157:105-132[CrossRef][Medline].
|
| 26.
|
Longnecker, R.,
C. L. Miller,
B. Tomkinson,
X. Q. Miao, and E. Kieff.
1993.
Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B.
J. Virol.
67:5068-5074[Abstract/Free Full Text].
|
| 27.
|
Mannick, J. B.,
J. I. Cohen,
M. Birkenbach,
A. Marchini, and E. Kieff.
1991.
The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation.
J. Virol.
65:6826-6837[Abstract/Free Full Text].
|
| 28.
|
Matsuno, K.,
R. J. Diederich,
M. J. Go,
C. M. Blaumueller, and S. Artavanis-Tsakonas.
1995.
Deltex acts as a positive regulator of Notch signaling through interactions with the Notch ankyrin repeats.
Development
121:2633-2644[Abstract].
|
| 29.
|
Matsuno, K.,
D. Eastman,
T. Mitsiades,
A. M. Quinn,
M. L. Carcanciu,
P. Ordentlich,
T. Kadesch, and S. Artavanis-Tsakonas.
1998.
Human deltex is a conserved regulator of Notch signalling.
Nat. Genet.
19:74-78[CrossRef][Medline].
|
| 30.
|
Matsuno, K.,
M. J. Go,
X. Sun,
D. S. Eastman, and S. Artavanis-Tsakonas.
1997.
Suppressor of Hairless-independent events in Notch signaling imply novel pathway elements.
Development
124:4265-4273[Abstract].
|
| 31.
|
Nofziger, D.,
A. Miyamoto,
K. M. Lyons, and G. Weinmaster.
1999.
Notch signaling imposes two distinct blocks in the differentiation of C2C12 myoblasts.
Development
126:1689-1702[Abstract].
|
| 32.
|
Ordentlich, P.,
A. Lin,
C. P. Shen,
C. Blaumueller,
K. Matsuno,
S. Artavanis-Tsakonas, and T. Kadesch.
1998.
Notch inhibition of E47 supports the existence of a novel signaling pathway.
Mol. Cell. Biol.
18:2230-2239[Abstract/Free Full Text].
|
| 33.
|
Oswald, F.,
S. Liptay,
G. Adler, and R. M. Schmid.
1998.
NF- B2 is a putative target gene of activated Notch-1 via RBP-J .
Mol. Cell. Biol.
18:2077-2088[Abstract/Free Full Text].
|
| 34.
|
Pan, D., and G. M. Rubin.
1997.
Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis.
Cell
90:271-280[CrossRef][Medline].
|
| 35.
|
Raab-Traub, N.
1996.
Pathogenesis of Epstein-Barr virus and its associated malignancies.
Semin. Virol.
7:315-323[CrossRef].
|
| 36.
|
Robertson, E. S.,
J. Lin, and E. Kieff.
1996.
The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa).
J. Virol.
70:3068-3074[Abstract].
|
| 37.
|
Sadler, R. H., and N. Raab-Traub.
1995.
Structural analyses of the Epstein-Barr virus BamHI A transcripts.
J. Virol.
69:1132-1141[Abstract].
|
| 38.
|
Schroeter, E. H.,
J. A. Kisslinger, and R. Kopan.
1998.
Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain.
Nature
393:382-386[CrossRef][Medline].
|
| 39.
|
Sjoblom, A.,
W. Yang,
L. Palmqvist,
A. Jansson, and L. Rymo.
1998.
An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter.
J. Virol.
72:1365-1376[Abstract/Free Full Text].
|
| 40.
|
Smith, P. R.,
O. de Jesus,
D. Turner,
M. Hollyoake,
C. E. Karstegl,
B. E. Griffin,
L. Karran,
Y. Wang,
S. D. Hayward, and P. J. Farrell.
2000.
Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus.
J. Virol.
74:3082-3092[Abstract/Free Full Text].
|
| 41.
|
Smith, P. R.,
Y. Gao,
L. Karran,
M. D. Jones,
D. Snudden, and B. E. Griffin.
1993.
Complex nature of the major viral polyadenylated transcripts in Epstein-Barr virus-associated tumors.
J. Virol.
67:3217-3225[Abstract/Free Full Text].
|
| 42.
|
Struhl, G., and A. Adachi.
1998.
Nuclear access and action of notch in vivo.
Cell
93:649-660[CrossRef][Medline].
|
| 43.
|
Sugaya, K.,
S. Sasanuma,
J. Nohata,
T. Kimura,
T. Fukagawa,
Y. Nakamura,
A. Ando,
H. Inoko,
T. Ikemura, and K. Mita.
1997.
Gene organization of human NOTCH4 and (CTG)n polymorphism in this human counterpart gene of mouse proto-oncogene Int3.
Gene
189:235-244[CrossRef][Medline].
|
| 44.
|
Tamura, K.,
Y. Taniguchi,
S. Minoguchi,
T. Sakai,
T. Tun,
T. Furukawa, and T. Honjo.
1995.
Physical interaction between a novel domain of the receptor Notch and the transcription factor RBP-J kappa/Su(H).
Curr. Biol.
5:1416-1423[CrossRef][Medline].
|
| 45.
|
Tomkinson, B., and E. Kieff.
1992.
Use of second-site homologous recombination to demonstrate that Epstein- Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro.
J. Virol.
66:2893-2903[Abstract/Free Full Text].
|
| 46.
|
Tomkinson, B.,
E. Robertson,
R. Yalamanchili,
R. Longnecker, and E. Kieff.
1993.
Epstein-Barr virus recombinants from overlapping cosmid fragments.
J. Virol.
67:7298-7306[Abstract/Free Full Text].
|
| 47.
|
Tsang, S. F.,
F. Wang,
K. M. Izumi, and E. Kieff.
1991.
Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression.
J. Virol.
65:6765-6771[Abstract/Free Full Text].
|
| 48.
|
Uyttendaele, H.,
G. Marazzi,
G. Wu,
Q. Yan,
D. Sassoon, and J. Kitajewski.
1996.
Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene.
Development
122:2251-2259[Abstract].
|
| 49.
|
Uyttendaele, H.,
J. V. Soriano,
R. Montesano, and J. Kitajewski.
1998.
Notch4 and Wnt-1 proteins function to regulate branching morphogenesis of mammary epithelial cells in an opposing fashion.
Dev. Biol.
196:204-217[CrossRef][Medline].
|
| 50.
|
Wang, F.,
S. F. Tsang,
M. G. Kurilla,
J. I. Cohen, and E. Kieff.
1990.
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.
J. Virol.
64:3407-3416[Abstract/Free Full Text].
|
| 51.
|
Young, L.,
C. Alfieri,
K. Hennessy,
H. Evans,
C. O'Hara,
K. C. Anderson,
J. Ritz,
R. S. Shapiro,
A. Rickinson, and E. Kieff.
1989.
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.
N. Engl. J. Med.
321:1080-1085[Abstract].
|
| 52.
|
Zhao, B.,
D. R. Marshall, and C. E. Sample.
1996.
A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of J .
J. Virol.
70:4228-4236[Abstract].
|
Journal of Virology, January 2001, p. 384-395, Vol. 75, No. 1
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.1.384-395.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Edwards, R. H., Marquitz, A. R., Raab-Traub, N.
(2008). Epstein-Barr Virus BART MicroRNAs Are Produced from a Large Intron prior to Splicing. J. Virol.
82: 9094-9106
[Abstract]
[Full Text]
-
Lin, J.-H., Tsai, C.-H., Chu, J.-S., Chen, J.-Y., Takada, K., Shew, J.-Y.
(2007). Dysregulation of HER2/HER3 Signaling Axis in Epstein-Barr Virus-Infected Breast Carcinoma Cells. J. Virol.
81: 5705-5713
[Abstract]
[Full Text]
-
Boccellato, F., Anastasiadou, E., Rosato, P., Kempkes, B., Frati, L., Faggioni, A., Trivedi, P.
(2007). EBNA2 Interferes with the Germinal Center Phenotype by Downregulating BCL6 and TCL1 in Non-Hodgkin's Lymphoma Cells. J. Virol.
81: 2274-2282
[Abstract]
[Full Text]
-
Chen, H., Huang, J., Wu, F. Y., Liao, G., Hutt-Fletcher, L., Hayward, S. D.
(2005). Regulation of Expression of the Epstein-Barr Virus BamHI-A Rightward Transcripts. J. Virol.
79: 1724-1733
[Abstract]
[Full Text]
-
Thornburg, N. J., Kusano, S., Raab-Traub, N.
(2004). Identification of Epstein-Barr Virus RK-BARF0-Interacting Proteins and Characterization of Expression Pattern. J. Virol.
78: 12848-12856
[Abstract]
[Full Text]
-
Everly, D. N. Jr., Kusano, S., Raab-Traub, N.
(2004). Accumulation of Cytoplasmic {beta}-Catenin and Nuclear Glycogen Synthase Kinase 3{beta} in Epstein-Barr Virus-Infected Cells. J. Virol.
78: 11648-11655
[Abstract]
[Full Text]
-
Xu, Y., Traystman, R. J., Hurn, P. D., Wang, M. M.
(2004). Membrane Restraint of Estrogen Receptor {alpha} Enhances Estrogen-Dependent Nuclear Localization and Genomic Function. Mol. Endocrinol.
18: 86-96
[Abstract]
[Full Text]
-
van Beek, J., Brink, A. A. T. P., Vervoort, M. B. H. J., van Zijp, M. J. M., Meijer, C. J. L. M., van den Brule, A. J. C., Middeldorp, J. M.
(2003). In vivo transcription of the Epstein-Barr virus (EBV) BamHI-A region without associated in vivo BARF0 protein expression in multiple EBV-associated disorders. J. Gen. Virol.
84: 2647-2659
[Abstract]
[Full Text]
-
de Jesus, O., Smith, P. R., Spender, L. C., Elgueta Karstegl, C., Niller, H. H., Huang, D., Farrell, P. J.
(2003). Updated Epstein-Barr virus (EBV) DNA sequence and analysis of a promoter for the BART (CST, BARF0) RNAs of EBV. J. Gen. Virol.
84: 1443-1450
[Abstract]
[Full Text]
-
Rivailler, P., Cho, Y.-g., Wang, F.
(2002). Complete Genomic Sequence of an Epstein-Barr Virus-Related Herpesvirus Naturally Infecting a New World Primate: a Defining Point in the Evolution of Oncogenic Lymphocryptoviruses. J. Virol.
76: 12055-12068
[Abstract]
[Full Text]
-
Kusano, S., Raab-Traub, N.
(2002). I-mfa Domain Proteins Interact with Axin and Affect Its Regulation of the Wnt and c-Jun N-Terminal Kinase Signaling Pathways. Mol. Cell. Biol.
22: 6393-6405
[Abstract]
[Full Text]
-
Lee, J. M., Lee, K.-H., Weidner, M., Osborne, B. A., Hayward, S. D.
(2002). Epstein-Barr virus EBNA2 blocks Nur77- mediated apoptosis. Proc. Natl. Acad. Sci. USA
99: 11878-11883
[Abstract]
[Full Text]
-
Hay, S., Kannourakis, G.
(2002). A time to kill: viral manipulation of the cell death program. J. Gen. Virol.
83: 1547-1564
[Abstract]
[Full Text]
-
Kang, M.-S., Hung, S. C., Kieff, E.
(2001). Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc. Natl. Acad. Sci. USA
10.1073/pnas.211556598v1
[Abstract]
[Full Text]
-
Kang, M.-S., Hung, S. C., Kieff, E.
(2001). Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc. Natl. Acad. Sci. USA
98: 15233-15238
[Abstract]
[Full Text]